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Introduction

1
Gallbladder carcinoma (GBC) is the most common malignancy of the biliary tract. Although 2 occurrence is rare as compared with other gastrointestinal tract neoplasms, including gastric and 3 colorectal cancers, GBC has a distinctly higher incidence in certain demographic groups and 4 geographic areas (1, 2). The prevalence of GBC in China, Thailand, and northern India is much higher 5 than in the United States and Europe (3). Surgical resection is currently the most effective and 6 potentially curative treatment for GBC. However, many patients present late in the course of the 7 disease when surgical intervention is no longer effective and most patients with advanced GBC 8 experience frequent recurrence after surgery. Therefore, the overall survival rate remains poor (4).
9
Although the most important risk factor for the development of GBC is cholelithiasis (up to 95% of 10 GBCs are associated with gallstones) (5), the molecular mechanisms involved in early carcinogenesis 11 and the factors affecting disease progression remain unclear. Therefore, identification of factors 12 crucial for GBC progression is necessary for the development of new therapeutic strategies.
13
Chemokines are 8-to 10-kilodalton chemoattractant cytokines that not only control leukocyte 14 trafficking and homing (6-9), but also play a major role in the trafficking, migration, and metastasis of 15 tumor cells released from the primary tumor expressing corresponding chemokine receptors to 16 particular sites (10-12). Chemokine (C-X-C motif) ligand 12 (CXCL12) is mainly expressed in 17 stromal fibroblasts of specific organs including the brain, breast, liver, bone, lung, and lymph nodes.
18
CXCL12 activates its receptor CXCR4, which is involved in cell proliferation, migration, and In this study, we determined CXCL12 expression and its relationship with clinicopathological 8 features and clinical outcomes in human GBC. We also clearly demonstrate that CXCL12 increased 9 proliferation, migration, and invasion, as well as activates intracellular ERK, AKT, and FAK signaling 10 in GBC cells in a CXCR4-dependent manner. To our knowledge, this is the first study showing the 11 expression of CXCL12 in GBC cells and its role in GBC progression. Taken together, these findings 12 suggest that CXCL12 may regulate tumor progression through an autocrine mechanism in GBC cells. 
Materials and Methods
16
Cell line and cell culture 17 SNU-308 cells, established from a well-differentiated gallbladder adenocarcinoma, were grown in 18 RPMI1640 media (Invitrogen) supplemented with 10% FBS. All cells were maintained at 37°C under 19 5% CO 2 and 95% relative humidity.
21
Patients and samples 22 We investigated 72 consecutive patients (33 men and 39 women) with GBC who underwent surgical triphosphates for 1 hour at 42°C. The reaction was quenched by heating for 15 minutes at 70°C.
10
Quantitative real-time PCR analyses were performed in a Rotor-gene 6000 thermocycler (Corbett
11
Research) using 1× SYBR Green mix (Invitrogen). 
17
Nonmigrating cells on the upper surface of the filter were removed by wiping with a cotton swab.
18
Chemotaxis was quantified by counting the cells that migrated to the lower side of the filter with an 19 optical microscope (×200). Eight random fields were counted for each assay.
21
Soft agar colony forming assay 22 Anchorage-independent growth assays were performed using the CytoSelect TM 96-well Cell measured by a WST-1 assay as described above. from GBC. Survival curves were plotted using the Kaplan-Meier method and analyzed using the log-1 rank test. Cox's proportional hazards model was performed to identify prognostic factors for survival. 
Results
9
Expression of CXCL12 in GBC
10
To analyze the function of CXCL12 in GBC progression, we first evaluated CXCL12 expression The median H score for GBC was 1.5. Based on these data, the patients were divided into CXCL12- (Table 1) . In addition, quantitative evaluation of CXCL12 mRNA expression in GBC tissues 20 (grade 0-3) by real-time PCR also showed that the mRNA levels from the grade 2 or 3 groups were 21 markedly higher than those for grade 0-1 groups (Fig. 1B) .
23
Correlation between CXCL12 expression and clinicopathologic factors 24 We next analyzed the correlation between CXCL12 expression and various clinicopathologic 25 factors that can affect the prognosis of patients with GBC. The results are summarized in Table 1 .
26
There was no significant difference in age, gender, pathologic T stage, distant metastasis, perineural To further investigate the clinical relevance of CXCL12 expression in GBC, we compared cancer-6 specific survival according to CXCL12 expression (Fig. 1C) . The median survival time of patients 7 with GBC was 13.5 (range, 1-117) months. Remarkably, the 10-year survival rates in the CXCL12-8 positive and -negative groups were 10 and 85.7%, respectively (P = 0.005), indicating a crucial 9 impact of CXCL12 expression on clinical outcome in patients.
10
Next, to estimate the clinical significance of various prognostic factors that might influence 11 survival in the study population, univariate analyses were performed. As summarized in Table 2,   12 advanced pathologic T stage (P = 0.002), nodal metastasis (P = 0.003), distant metastasis (P = 0.045), 13 differentiation (P = 0.023), lymphatic invasion (P = 0.001), and CXCL12 expression (P = 0.012) were 14 statistically significant risk factors affecting overall survival of patients with GBC. To further 15 determine the independent prognostic impacts of these various factors, multivariate analyses were 16 performed using the Cox's proportional-hazards model. These analyses showed that CXCL12 17 expression (HR, 8.675; 95% CI, 1.554-48.413; P = 0.014) was an independent risk factor predicting 18 cancer-specific survival in patients with GBC (Table 2) . Taken together, our findings indicate that 19 CXCL12 expression may be a useful marker to predict the survival of patients with GBC. independent growth of the cells (Fig. 2C-2D ). To further confirm the effect of CXCL12 on the growth 1 of GBC cells, SNU-308 cells were stably transfected with full-length human CXCL12 and the cell 2 lines showing high level expression of CXCL12 were selected. Elevated CXCL12 levels were 3 confirmed by Western blot analyses (Fig. 2E) . Consistently, CXCL12 overexpressing cells showed 4 significantly enhanced cell growth compared with the control mock-transfected cells (Fig. 2E) . Next, (Fig. 3A-3D) . Consistently, CXCL12-overexpressing cells displayed significantly 19 increased migration and invasion as compared with control cells (Supplementary Fig. 1A-1B) . In 20 addition, CXCL12 increased the adhesion of GBC cells to matrix components such as fibronectin, 21 collagen, laminin, and vitronectin (Fig. 3E ).
22
One important feature of tumor cells is the ability to regulate their survival. Therefore, we Fig. 2A-2C ). These results suggest that the CXCR4/CXCL12 system plays an important role in the 14 growth, migration, and invasion of GBC cells.
16
Discussion
17
In the present study, we demonstrate for the first time that CXCL12 is expressed differentially in
18
GBCs and is associated with GBC progression. In addition, CXCL12 expression is an independent in gastric cancer (33). In addition, CXCL12-positive patients showed significantly poorer oncologic 1 outcomes than did the CXCL12-negative patients, suggesting CXCL12 is an independent prognostic 2 factor in gastric cancer. Salmaggi et al. also showed that CXCL12 expression was correlated with a 3 significantly shorter time to progression in glioma as an independent predictor (30). A similar pattern 4 has been reported for colon cancer (32), esophageal cancer (31), malignant glioma (36), and non-5 small cell lung cancer (37). However, CXCL12 expression and its clinical relevance in GBC have not 6 yet been investigated. In this study, we observed overexpression of CXCL12 in GBC. Moreover, we 7 demonstrated that CXCL12 expression was significantly associated with a high histologic grade and 8 lymph node metastasis and is an independent poor risk factor for predicting survival in patients with 9 GBC. Our results suggest that CXCL12 could be involved in GBC tumorigenesis and be useful as a 10 potential prognostic biomarker for GBC patients. Fig. 2A-2C ).
5
These observations suggest that the CXCL12/CXCR4 axis plays a critical role in the tumorigenesis of 6 GBC. Table 1 and Supplementary Fig. 3B ).
13
These results suggest that CXCL12 expression may play an important functional role in GBC 14 progression whereas CXCR4 alone may not. 
